Jenburkt Pharmaceuticals Ltd

As of March 31, 2026, Jenburkt Pharmaceuticals Ltd has 4.41M shares outstanding.

As of March 31, 2026, Jenburkt Pharmaceuticals Ltd maintains a current ratio of 4.11, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Jenburkt Pharmaceuticals Ltd recorded 76.14M in income tax expense.

As of March 31, 2026, Jenburkt Pharmaceuticals Ltd holds 473.16M in cash and equivalents against 24.88M in total debt, resulting in a net debt position of -55.77M. Total book value stands at 1.97B, with working capital of 719.43M providing operational flexibility.